Organogenesis Apligraf
This article was originally published in The Gray Sheet
Executive Summary
Novartis Pharma is set to resume shipments of the bi-layered, living skin substitute under an agreement announced Nov. 20. Novartis suspended its distribution in September after the companies failed to agree on an amended arrangement ("1The Gray Sheet" Sept. 30, 2002, In Brief). Under the new arrangement, the licensing and distribution rights to Apligraf will revert to Organogenesis in June 2003. Subject to approval of a Boston bankruptcy court, the deal is part of a Chapter 11 reorganizing plan filed by Organogenesis in September...